默克公司的实验性Favezelimab/Keytruda组合在癌症晚期结直肠癌研究中失败-动脉网

Merck's Experimental Favezelimab/Keytruda Combo Fails In Late-Stage Colorectal Cancer Study

benzinga 等信源发布 2024-09-25 08:32



可切换为仅中文







On Wednesday, Merck & Co Inc MRK released topline data from the KEYFORM-007 Phase 3 study of the fixed-dose combination of favezelimab and pembrolizumab versus the standard of care for pretreated patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).

周三，默克公司（Merck＆Co Inc）MRK发布了来自KEYFORM-007第三阶段研究的topline数据，该研究涉及固定剂量的favezelimab和pembrolizumab联合治疗与微卫星稳定（MSS）转移性结直肠癌（mCRC）预治疗患者的标准治疗。

The US drug giant said the study did not meet its primary endpoint of overall survival.

这家美国制药巨头表示，这项研究没有达到总体生存的主要终点。

Also Read: Merck’s Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer.

另请阅读：默克公司的Keytruda首次获得FDA对罕见侵袭性癌症的批准。

At the final pre-specified analysis, the favezelimab and pembrolizumab fixed-dose combination did not demonstrate an improvement in OS compared to standard of care (regorafenib or TAS-102 [trifluridine and tipiracil hydrochloride]).

在最终的预先指定的分析中，与标准治疗（瑞格非尼或TAS-102[三氟尿苷和盐酸替吡拉西]）相比，法维西单抗和派姆单抗固定剂量组合没有显示OS的改善。

The safety profile of the fixed-dose combination was consistent with that observed for favezelimab and pembrolizumab in previously reported studies, with no new safety signals observed.

固定剂量组合的安全性与先前报道的研究中观察到的favezelimab和pembrolizumab的安全性一致，没有观察到新的安全信号。

A full data evaluation is ongoing.

正在进行全面的数据评估。

In the U.S., Keytruda is approved for patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.

在美国，Keytruda被批准用于不可切除或转移性微卫星不稳定性高（MSI-H）或错配修复缺陷（dMMR）结直肠癌患者。

Keytruda has not been approved for the treatment of MSS mCRC.

Keytruda尚未被批准用于治疗MSS mCRC。

Last month, Merck stopped two Keytruda Phase 3 trials, KEYNOTE-867 and KEYNOTE-630, after underwhelming data.

上个月，默克公司停止了KEYNOTE-867和KEYNOTE-630两项Keytruda 3期临床试验，因为数据不太令人满意。

Concurrently, on Wednesday, Japan’s drug regulator approved new indications for Keytruda (pembrolizumab), in certain lung and urothelial cancers.

同时，周三，日本药物监管机构批准了某些肺癌和尿路上皮癌中Keytruda（pembrolizumab）的新适应症。

Merck Stock Prediction For 2024

默克公司2024年股票预测

Equity research can be a valuable source of information for learning about a company's fundamentals. Analysts create financial models based on the fundamentals and expected future earnings of a company to arrive at a price target and recommendation for the stock.

股权研究可以成为了解公司基本面的宝贵信息来源。分析师根据公司的基本面和预期未来收益创建财务模型，以达成股票的价格目标和建议。

Shares of Merck & Co have an average 1-year price target of $142.57, representing an expected upside of 24.02%.

默克公司（Merck&Co.）股票的1年平均价格目标为142.57美元，预计上涨24.02%。

Because of differences in assumptions, analysts can arrive at very different price targets and recommendations. No analysts have bearish recommendations on Merck & Co, while 5 analysts have bullish ratings. The street high price target from Cantor Fitzgerald is $155.0, while the street low from Wells Fargo is $125.0..

由于假设的不同，分析师可以得出非常不同的价格目标和建议。没有分析师对默克公司持看跌态度，而有5位分析师持看涨评级。康托·菲茨杰拉德（Cantor Fitzgerald）的街头高价目标价为155.0美元，而富国银行（Wells Fargo）的街头低价目标价为125.0美元。。

Price Action: MRK stock is down 0.10% at $114.85 during the premarket session at last check on Wednesday.

价格走势：MRK股价在周三最后一次检查的上市前交易中下跌0.10%，至114.85美元。